SCM
Soleus Capital Management Portfolio holdings
AUM
$1.45B
This Quarter Return
+5.38%
1 Year Return
+18.23%
3 Year Return
+274.85%
5 Year Return
+440.77%
10 Year Return
–
AUM
$650M
AUM Growth
+$650M
(+17%)
Cap. Flow
+$97.7M
Cap. Flow
% of AUM
15.02%
Top 10 Holdings %
Top 10 Hldgs %
57.73%
Holding
90
New
18
Increased
17
Reduced
23
Closed
25
Top Buys
| 1 |
Neuropace
NPCE
|
$32.9M |
| 2 |
CRISPR Therapeutics
CRSP
|
$16.7M |
| 3 |
EDAP
EDAP TMS
EDAP
|
$16.5M |
| 4 |
NovoCure
NVCR
|
$16.3M |
| 5 |
C4 Therapeutics
CCCC
|
$15.4M |
Top Sells
| 1 |
BioAtla
BCAB
|
$16.3M |
| 2 |
Xenon Pharmaceuticals
XENE
|
$8.83M |
| 3 |
Krystal Biotech
KRYS
|
$6.75M |
| 4 |
Galecto
GLTO
|
$4.93M |
| 5 |
FLXN
Flexion Therapeutics, Inc.
FLXN
|
$4.68M |
Sector Composition
| 1 | Healthcare | 90.8% |
| 2 | Consumer Staples | 2.41% |
| 3 | Financials | 0.49% |
| 4 | Real Estate | 0.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Y-mAbs Therapeutics
YMAB
$390M
| $4.88M | 0.75% |
+144,300
| New | +$4.88M |
|
|
CMPS
27
Compass Pathways
CMPS
$452M
| $4.87M | 0.75% |
127,743
+85,000
| +199% | +$3.24M |
|
|
28
Krystal Biotech
KRYS
$4.35B
| $4.59M | 0.71% |
67,529
-99,315
| -60% | -$6.75M |
|
29
Assembly Biosciences
ASMB
$183M
| $4.35M | 0.67% |
1,122,000
| – | – |
|
|
30
Xenon Pharmaceuticals
XENE
$2.99B
| $4.35M | 0.67% |
233,697
-474,420
| -67% | -$8.83M |
|
31
Inspire Medical Systems
INSP
$2.53B
| $4.17M | 0.64% |
+21,550
| New | +$4.17M |
|
32
MiMedx Group
MDXG
$1.05B
| $4.03M | 0.62% |
322,160
-177,840
| -36% | -$2.22M |
|
33
Revolution Medicines
RVMD
$7.43B
| $3.99M | 0.61% |
125,700
+68,500
| +120% | +$2.17M |
|
34
Celcuity
CELC
$2.3B
| $3.96M | 0.61% |
+164,824
| New | +$3.96M |
|
35
Pulmonx
LUNG
$67.6M
| $3.76M | 0.58% |
+85,250
| New | +$3.76M |
|
36
Dyne Therapeutics
DYN
$1.92B
| $3.75M | 0.58% |
178,360
+4,000
| +2% | +$84.2K |
|
37
Axogen
AXGN
$718M
| $3.42M | 0.53% |
+158,140
| New | +$3.42M |
|
|
ARYD
38
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
| $3.22M | 0.49% |
300,000
| – | – |
|
39
Beam Therapeutics
BEAM
$1.9B
| $2.84M | 0.44% |
+22,100
| New | +$2.84M |
|
|
40
Galecto
GLTO
$3.93M
| $2.72M | 0.42% |
538,152
-974,496
| -64% | -$4.93M |
|
41
Alpha Teknova
TKNO
$227M
| $2.72M | 0.42% |
+114,546
| New | +$2.72M |
|
42
CareDx
CDNA
$678M
| $2.68M | 0.41% |
+29,300
| New | +$2.68M |
|
43
DexCom
DXCM
$30.9B
| $2.51M | 0.39% |
5,884
-1,051
| -15% | -$449K |
|
44
Insulet
PODD
$24.2B
| $2.47M | 0.38% |
+8,980
| New | +$2.47M |
|
45
4D Molecular Therapeutics
FDMT
$302M
| $2.43M | 0.37% |
100,800
+14,700
| +17% | +$354K |
|
46
Establishment Labs
ESTA
$1.11B
| $2.32M | 0.36% |
26,568
-34,583
| -57% | -$3.02M |
|
|
MSON
47
DELISTED
Misonix Inc
MSON
| $2.24M | 0.34% |
100,788
-200,545
| -67% | -$4.45M |
|
48
Guardant Health
GH
$8.11B
| $2.17M | 0.33% |
+17,500
| New | +$2.17M |
|
49
Halozyme
HALO
$8.75B
| $2M | 0.31% |
+44,100
| New | +$2M |
|
50
Rafael Holdings
RFL
$53.4M
| $1.88M | 0.29% |
36,742
-48,895
| -57% | -$2.5M |
|